NantCapital

ImmunityBio, Inc. is an immunotherapy company focused on developing innovative treatments that enhance the body's immune response to combat various cancers without relying on high-dose chemotherapy. The company's product pipeline includes a memory T-cell cancer vaccine, albumin-linked chemotherapeutics, a novel IL-15 cytokine superagonist known as Anktiva, checkpoint inhibitors, and various vaccine therapies targeting specific tumor-associated antigens. Incorporated in 2014 and headquartered in El Segundo, California, ImmunityBio aims to address multiple tumor types, including bladder, lung, and colorectal cancers, as well as glioblastoma. The company is a subsidiary of NantWorks, LLC, and is actively engaged in clinical development to bring its next-generation immuno- and cellular therapies to market.

ImmunityBio, Inc. is an immunotherapy company focused on developing innovative treatments that enhance the body's immune response to combat various cancers without relying on high-dose chemotherapy. The company's product pipeline includes a memory T-cell cancer vaccine, albumin-linked chemotherapeutics, a novel IL-15 cytokine superagonist known as Anktiva, checkpoint inhibitors, and various vaccine therapies targeting specific tumor-associated antigens. Incorporated in 2014 and headquartered in El Segundo, California, ImmunityBio aims to address multiple tumor types, including bladder, lung, and colorectal cancers, as well as glioblastoma. The company is a subsidiary of NantWorks, LLC, and is actively engaged in clinical development to bring its next-generation immuno- and cellular therapies to market.

NantHealth is a healthcare company focused on transforming the delivery of care through an evidence-based platform that integrates science and technology. The company specializes in precision medicine, developing software and hardware that collect, index, analyze, and interpret molecular, financial, clinical, and operational data. This comprehensive approach aims to empower physicians, patients, payers, and researchers by providing them with crucial information to make informed decisions. NantHealth's solutions enhance diagnostics, enabling better identification and targeting of specific disease characteristics, particularly in cancer care. By promoting an integrated, genomically-informed, and personalized approach, the company seeks to advance clinical delivery and foster overall wellness in healthcare.

ImmunityBio, Inc. is an immunotherapy company focused on developing innovative treatments that enhance the body's immune response to combat various cancers without relying on high-dose chemotherapy. The company's product pipeline includes a memory T-cell cancer vaccine, albumin-linked chemotherapeutics, a novel IL-15 cytokine superagonist known as Anktiva, checkpoint inhibitors, and various vaccine therapies targeting specific tumor-associated antigens. Incorporated in 2014 and headquartered in El Segundo, California, ImmunityBio aims to address multiple tumor types, including bladder, lung, and colorectal cancers, as well as glioblastoma. The company is a subsidiary of NantWorks, LLC, and is actively engaged in clinical development to bring its next-generation immuno- and cellular therapies to market.

ImmunityBio, Inc. is an immunotherapy company focused on developing innovative treatments that enhance the body's immune response to combat various cancers without relying on high-dose chemotherapy. The company's product pipeline includes a memory T-cell cancer vaccine, albumin-linked chemotherapeutics, a novel IL-15 cytokine superagonist known as Anktiva, checkpoint inhibitors, and various vaccine therapies targeting specific tumor-associated antigens. Incorporated in 2014 and headquartered in El Segundo, California, ImmunityBio aims to address multiple tumor types, including bladder, lung, and colorectal cancers, as well as glioblastoma. The company is a subsidiary of NantWorks, LLC, and is actively engaged in clinical development to bring its next-generation immuno- and cellular therapies to market.

Heliogen, Inc. is a clean energy technology company based in Pasadena, California, founded in 2013. It specializes in using concentrated solar power to produce renewable fuels such as hydrogen and syngas, aiming to eliminate reliance on fossil fuels in heavy industry. The company has developed innovative systems, including HelioMax, a closed-loop control system for electricity generation and process heat applications, and HelioHeat, which provides carbon-free, ultra-high-temperature heat for sectors like cement, refining, and mining. Heliogen’s AI-enabled modular technology enables the cost-effective delivery of continuous carbon-free energy in the form of heat, power, or green hydrogen, marking a significant advancement in sustainable energy solutions.

Heliogen, Inc. is a clean energy technology company based in Pasadena, California, founded in 2013. It specializes in using concentrated solar power to produce renewable fuels such as hydrogen and syngas, aiming to eliminate reliance on fossil fuels in heavy industry. The company has developed innovative systems, including HelioMax, a closed-loop control system for electricity generation and process heat applications, and HelioHeat, which provides carbon-free, ultra-high-temperature heat for sectors like cement, refining, and mining. Heliogen’s AI-enabled modular technology enables the cost-effective delivery of continuous carbon-free energy in the form of heat, power, or green hydrogen, marking a significant advancement in sustainable energy solutions.

PacketFabric, Inc. is a technology company that specializes in providing a Network-as-a-Service platform focused on Ethernet-based cloud networking services. Founded in 2015 and based in Culver City, California, the company enables businesses to procure, manage, and consume their network connectivity with an emphasis on security and control. Its platform is designed to facilitate scalable and secure connections between colocation facilities, major cloud providers, and Internet exchanges. Utilizing a software-defined networking architecture, PacketFabric offers automated, real-time connectivity services that operate at terabit scale, allowing enterprises to streamline their data movement through dynamic network management. All services are accessible via the company's user-friendly portal and API, making it a cost-effective solution for modern networking needs.

Benitec Biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases. Their transformational technology, ddRNAi, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. Compared to traditional approaches to RNA intereference, ddRNAi is easier to deliver, safer to us, more targeted and more efficient. Benitec has a pipeline of in-house and partnered drug development programs based on ddRNAI, including Hepatitis C and B, cancer-associated pain and drug-resistant lung cancer. Our Hepatitis C program is nearing clinical trials in 2013. ddRNAi has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. The technology is available from Benitec under a variety of licence options.

Veradigm provides health industry software. The company is based in Chicago, Illinois. Allscripts, LLC was formerly a subsidiary of Allscripts Healthcare Solutions Inc. As a result of the acquisition of Allscripts Healthcare Solutions Inc. by Allscripts-Misys Healthcare Solutions, Inc. as of October 10, 2008, Allscripts, LLC operates as a subsidiary of Allscripts-Misys Healthcare Solutions, Inc.